FFA
MLTX icon

Farther Finance Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Farther Finance Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.3K Buy
883
+150
+20% +$2.72K ﹤0.01% 4080
2026
Q1 		$12.1K Sell
733
-38
-5% -$629 ﹤0.01% 3979
2025
Q4 		$10.2K Buy
771
+746
+2,984% +$8.8K ﹤0.01% 3894
2025
Q3 		$179 Buy
+25
New +$1.3K ﹤0.01% 4744

Other funds holding MLTX

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Farther Finance Advisors's MLTX Position: Q2 2026 in Review

Farther Finance Advisors increased its MoonLake Immunotherapeutics (MLTX) stake by 20% in Q2 2026, buying an estimated $2.72K and bringing the position to 883 shares worth $17.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4080.

Farther Finance Advisors first reported a position in MLTX in Q3 2025 and has held it in 4 quarters since. 6 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Farther Finance Advisors held 883 shares of MoonLake Immunotherapeutics worth $17.3K as of Q2 2026.
  • Farther Finance Advisors bought 150 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $2.72K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #4080 holding.
  • Farther Finance Advisors first reported a position in MoonLake Immunotherapeutics in Q3 2025 and has held it in 4 quarters since.
  • 6 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.